Clinical Trial Update: RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating a neuroplasticity agent combined with constraint-induced therapy for severe arm paresis after stroke has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Neuroplasticity agent

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Severe Stroke With Affected Arm Motor Function | Phase 2 | Status: WITHDRAWN